Mode
Text Size
Log in / Sign up

Pancreatic adenocarcinoma

Part of Cancer

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials for pancreatic adenocarcinoma

28 trials tracked for pancreatic adenocarcinoma: 3 in phase 3 or 4 and 2 with published results. The most-cited published study has 13 citations.

28Trials tracked
3Phase 3 & 4
0Recruiting
2With published results
Phase distribution
Phase 3 3 Phase 2 19 Phase 1 2 Other / NA 4
  1. Phase 3 Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery Completed · 13 cited
  2. Phase 3 Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone as 2nd-Line Treatment in PAC Completed · 2 cited
  3. Phase 3 EndoTAG-1+GEM vs GEM in Patients With Locally Advanced/Metastatic Pancreatic Adenocarcinoma Failed on FOLFIRINOX Completed
  4. Phase 2 Trial Investigating an Immunostimulatory Oncolytic Adenovirus for Cancer Completed
  5. Phase 2 Pre-operative Treatment for Patients With Untreated Pancreatic Cancer Completed
  6. Phase 2 A Pilot Study of Pre- and Post-surgery Chemotherapy With mFOLFIRINOX in Localized, Resectable Pancreatic Adenocarcinoma Completed
Show 22 more trials
  1. Phase 2 Niraparib + Ipilimumab or Nivolumab in Progression Free Pancreatic Adenocarcinoma After Platinum-Based Chemotherapy Completed
  2. Phase 2 Perioperative Therapy for Resectable and Borderline-Resectable Pancreatic Adenocarcinoma With Molecular Correlates Completed
  3. Phase 2 Study of the Safety and Efficacy of TH-302 in Combination With Gemcitabine Compared With Gemcitabine Alone in Previously Untreated Patients With Pancreatic Adenocarcinoma Completed
  4. Phase 2 Nab-paclitaxel and Gemcitabine Hydrochloride Followed by Radiation Therapy Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery Completed
  5. Phase 2 Study of CAP1-6D in Patients With Locally Advanced or Surgically Resected Pancreatic Adenocarcinoma Completed
  6. Phase 2 Gemcitabine and Nab-Paclitaxel vs Gemcitabine, Nab-Paclitaxel, Durvalumab and Tremelimumab as 1st Line Therapy in Metastatic Pancreatic Adenocarcinoma Completed
  7. Phase 2 Trial of Gemcitabine With or Without MSC1936369B in Pancreatic Cancer Completed
  8. Phase 2 Chemotherapy, Stereotactic Body Radiation Therapy & Nelfinavir Mesylate in Locally Advanced Pancreatic Cancer Completed
  9. Phase 2 A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer) Completed
  10. Phase 2 Pancreas Cancer: Molecular Profiling as a Guide to Therapy Before and After Surgery ("Personalized Medicine") Completed
  11. Phase 2 Role of Interim 18F-FLT PET/CT for Outcome Prediction in Pancreatic Adenocarcinoma Completed
  12. Phase 2 Paclitaxel Protein Bound Plus Cisplatin Plus Gemcitabine and Paricalcitol for Pancreatic Adenocarcinoma (NABPLAGEMD) Completed
  13. Phase 2 MK-0646 and Gemcitabine +/- Erlotinib for Patients With Advanced Pancreatic Cancer Completed
  14. Phase 2 S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery Completed
  15. Phase 2 Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer Completed
  16. Phase 2 A Randomized Phase II/Genomic Trial of Two Chemotherapy Regimens in Patients With Resected Pancreatic Adenocarcinoma Completed
  17. Phase 1 Mesothelin-Targeted Immunotoxin LMB-100 in Combination With Tofacitinib in Persons With Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and Other Mesothelin Expressing Solid Tumors Completed
  18. Phase 1 Ascorbic Acid and Combination Chemotherapy in Treating Patients With Locally Advanced or Recurrent Pancreatic Cancer That Cannot Be Removed by Surgery Completed
  19. N/A Pancreatic Juice Diagnosis From Duodenum Completed
  20. N/A Radiopaque Hydrogel in Patients Undergoing Radiotherapy for Pancreatic Cancer Completed
  21. N/A 4D-CT for Pancreatic Adenocarcinoma in Radiotherapy Simulation Completed
  22. N/A The Impact Of Tissue Micro-RNA Profile From EUS-FNA In Pancreatic Adenocarcinoma Completed

Showing the 28 most-cited and recently-updated of 28 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.

Research across Cancer

Related studies from across the Cancer family.

Nanomedicine strategies show promise for targeting pancreatic ductal adenocarcinoma
Infectious Disease Sys. Review
Nanomedicine strategies show promise for targeting pancreatic ductal adenocarcinoma Nanomedicine options for pancreatic cancer remain theoretical in current reviews
This narrative review surveys nanomedicine approaches for pancreatic ductal adenocarcinoma, including polymeric nanoparticles, small-molecul…
Current reviews suggest nanomedicine and other advanced therapies for pancreatic cancer are still theoretical concepts without proven clinic…
Narrative review on KMT2C alterations in gastrointestinal cancers and therapeutic implications
Allergy & Immunology Sys. Review
Narrative review on KMT2C alterations in gastrointestinal cancers and therapeutic implications Genetic changes in gut cancers may open new treatment doors for patients
This narrative review synthesizes evidence on KMT2C alterations across gastrointestinal malignancies. It links KMT2C dysfunction to transcri…
A review of genetic changes in gastrointestinal cancers suggests new ways to treat tumors by targeting specific DNA repair weaknesses.
Guideline-based case report: neoadjuvant alectinib in ALK-rearranged stage IIIB lung cancer
Drug Pipeline Guideline
Guideline-based case report: neoadjuvant alectinib in ALK-rearranged stage IIIB lung cancer One woman shows how alectinib shrinks lung cancer before surgery
This guideline-based case report describes a 57-year-old woman with ALK-rearranged stage IIIB lung cancer treated with neoadjuvant alectinib…
A single case shows alectinib shrinking lung cancer before surgery. This report offers hope for specific patients but needs more study.
Case report and literature review on IgG4-related disease misdiagnosed as pancreatic cancer in a 70-year-old male
Rheumatology Meta-analysis
Case report and literature review on IgG4-related disease misdiagnosed as pancreatic cancer in a 70-year-old male A 70-year-old man avoided unnecessary surgery after doctors found a treatable autoimmune condition
This case report and literature review examines a 70-year-old male patient with IgG4-related autoimmune pancreatitis initially suspected as …
A 70-year-old man with a pancreatic mass was found to have a treatable autoimmune disease, sparing him from unnecessary surgery.
Robot-assisted distal pancreatectomy reduces blood loss and conversions but increases operative time and cost
Oncology Meta-analysis
Robot-assisted distal pancreatectomy reduces blood loss and conversions but increases operative time and cost Robot Surgery Matches Laparoscopic for Pancreas Cancer Outcomes
This systematic review and meta-analysis of 15790 patients undergoing distal pancreatectomy found that robot-assisted distal pancreatectomy …
New data shows robot-assisted pancreas surgery matches standard laparoscopic methods in safety and cancer control, while cutting blood loss …
FDA approves OPDIVO QVANTIG for multiple advanced cancer indications including renal cell carcinoma and melanoma
Oncology FDA Approval
FDA approves OPDIVO QVANTIG for multiple advanced cancer indications including renal cell carcinoma and melanoma FDA approves subcutaneous nivolumab combination for multiple advanced cancers
This FDA approval document grants authorization for OPDIVO QVANTIG, a subcutaneous combination of nivolumab and hyaluronidase, for specified…
The FDA has approved a new subcutaneous form of nivolumab for several advanced cancers, offering a more convenient treatment option for elig…
Case report on ivonescimab for EGFR-TKI-resistant lung adenocarcinoma with pericardial effusion
Infectious Disease Sys. Review
Case report on ivonescimab for EGFR-TKI-resistant lung adenocarcinoma with pericardial effusion One Drug Shrinks Lung Tumors When Others Stop Working
This is a case report and literature review of a 77-year-old female with EGFR-TKI-resistant advanced lung adenocarcinoma and malignant peric…
A 77-year-old woman with advanced lung cancer saw her tumors shrink and dangerous fluid around her heart disappear after trying a new drug c…
Case report and literature review on oxaliplatin and tegafur for AEG with intramural metastasis
Oncology Sys. Review
Case report and literature review on oxaliplatin and tegafur for AEG with intramural metastasis A rare cancer spread inside the esophagus wall needs careful treatment plans for older adults
This case report and literature review examines a 77-year-old male with adenocarcinoma of the esophagogastric junction and esophageal intram…
A doctor reviewed a rare case where cancer spread inside the esophagus wall. This condition often means the disease is already in the body. …
Systematic review and meta-analysis of survival outcomes in HPV-independent versus HPV-associated cervical adenocarcinoma
Oncology Meta-analysis
Systematic review and meta-analysis of survival outcomes in HPV-independent versus HPV-associated cervical adenocarcinoma One Type of Cervical Cancer Is Far More Dangerous Than Others
This systematic review and meta-analysis synthesized comparative studies on HPV-independent and HPV-associated cervical adenocarcinoma. It f…
A large new analysis reveals that women with HPV-negative cervical adenocarcinoma face nearly three times the risk of death compared to thos…
Meta-analysis shows neoadjuvant chemoradiation improves resection and survival outcomes for esophageal squamous cell carcinoma patients compared to chemotherapy alone
ENT (Otolaryngology) Meta-analysis
Meta-analysis shows neoadjuvant chemoradiation improves resection and survival outcomes for esophageal squamous cell carcinoma patients compared to chemotherapy alone Adding radiation before surgery helps some esophageal cancer patients get better surgery results and live longer
This meta-analysis of 2,174 patients reveals that adding radiation to chemotherapy significantly boosts resection rates and survival for squ…
A large review found that adding radiation to chemotherapy before surgery helped remove more tumors in certain cancer types. This approach a…
TaTME shows lower conversion rates with similar short-term safety compared to LapTME for low rectal cancer
Gastroenterology RCT
TaTME shows lower conversion rates with similar short-term safety compared to LapTME for low rectal cancer New surgical approach for rectal cancer cuts conversion rate
This randomized trial compared transanal total mesorectal excision with laparoscopic total mesorectal excision for patients with low rectal …
A new surgical technique for rectal cancer reduces the need to switch to open surgery, with similar complication rates.
AI models improve diagnostic accuracy for pancreatic ductal adenocarcinoma compared to conventional methods
Radiology & Imaging Meta-analysis
AI models improve diagnostic accuracy for pancreatic ductal adenocarcinoma compared to conventional methods AI models improve pancreatic cancer diagnosis accuracy in large review
This systematic review and meta-analysis evaluated radiomics-based models derived from computed tomography, magnetic resonance imaging, posi…
A large review shows AI tools using scans can detect pancreatic cancer with higher accuracy than standard methods, offering hope for earlier…